PharmaResearch Co., Ltd. (214450.KQ)
KRW 259500.0
(2.77%)
KRW 259500.0
(2.77%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 104.25 Billion KRW | 35.99% |
| 2022 | 76.51 Billion KRW | 23.61% |
| 2021 | 66.21 Billion KRW | 48.43% |
| 2020 | 41.78 Billion KRW | 56.24% |
| 2019 | 29.53 Billion KRW | 100.99% |
| 2018 | 20.18 Billion KRW | -17.18% |
| 2017 | 16.14 Billion KRW | 5.37% |
| 2016 | 18.4 Billion KRW | -10.96% |
| 2015 | 17.38 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 33.9 Billion KRW | 42.37% |
| 2024 Q1 | 29.82 Billion KRW | 1.14% |
| 2023 Q4 | 23.52 Billion KRW | -23.01% |
| 2023 Q2 | 26.6 Billion KRW | 12.9% |
| 2023 Q1 | 23.56 Billion KRW | 20.43% |
| 2023 Q3 | 30.55 Billion KRW | 14.86% |
| 2023 FY | - KRW | 35.99% |
| 2022 Q1 | 17.68 Billion KRW | 17.46% |
| 2022 FY | - KRW | 23.61% |
| 2022 Q4 | 19.56 Billion KRW | 1.52% |
| 2022 Q2 | 20.13 Billion KRW | 13.85% |
| 2022 Q3 | 19.27 Billion KRW | -4.28% |
| 2021 Q1 | 14.65 Billion KRW | 8.09% |
| 2021 Q2 | 16.25 Billion KRW | 10.91% |
| 2021 Q3 | 16.05 Billion KRW | -1.26% |
| 2021 Q4 | 15.05 Billion KRW | -6.19% |
| 2021 FY | - KRW | 48.43% |
| 2020 Q2 | 10.06 Billion KRW | 53.21% |
| 2020 Q3 | 11.58 Billion KRW | 15.11% |
| 2020 Q4 | 13.55 Billion KRW | 17.01% |
| 2020 FY | - KRW | 56.24% |
| 2020 Q1 | 6.57 Billion KRW | -25.25% |
| 2019 Q2 | 6.01 Billion KRW | -9.71% |
| 2019 FY | - KRW | 100.99% |
| 2019 Q4 | 8.79 Billion KRW | 66.21% |
| 2019 Q3 | 5.28 Billion KRW | -12.0% |
| 2019 Q1 | 6.65 Billion KRW | 154.94% |
| 2018 FY | - KRW | -17.18% |
| 2018 Q4 | 2.61 Billion KRW | -9.9% |
| 2018 Q3 | 2.89 Billion KRW | -13.3% |
| 2018 Q1 | 4.87 Billion KRW | 1348.11% |
| 2018 Q2 | 3.34 Billion KRW | -31.42% |
| 2017 Q3 | 6.15 Billion KRW | 48.86% |
| 2017 Q2 | 4.13 Billion KRW | -25.23% |
| 2017 Q1 | 5.52 Billion KRW | 186.55% |
| 2017 FY | - KRW | 5.37% |
| 2017 Q4 | 336.56 Million KRW | -94.53% |
| 2016 Q4 | 1.92 Billion KRW | -61.46% |
| 2016 Q1 | 3.9 Billion KRW | -12.87% |
| 2016 FY | - KRW | -10.96% |
| 2016 Q3 | 5 Billion KRW | 13.38% |
| 2016 Q2 | 4.41 Billion KRW | 13.15% |
| 2015 FY | - KRW | 0.0% |
| 2015 Q4 | 4.47 Billion KRW | -12.54% |
| 2015 Q3 | 5.11 Billion KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| HLB Co., Ltd. | -172.27 Billion KRW | 160.515% |
| iNtRON Biotechnology, Inc. | -6.23 Billion KRW | 1772.166% |
| BINEX Co., Ltd. | 10.87 Billion KRW | -858.916% |
| Bioneer Corporation | 10.04 Billion KRW | -938.052% |
| Anterogen.Co.,Ltd. | -437.82 Million KRW | 23911.776% |
| MEDIPOST Co., Ltd. | -19.39 Billion KRW | 637.622% |
| CrystalGenomics, Inc. | -42.79 Billion KRW | 343.6% |
| Helixmith Co., Ltd | -53 Billion KRW | 296.69% |
| Chabiotech Co.,Ltd. | 70.08 Billion KRW | -48.747% |
| Medy-Tox Inc. | 32.69 Billion KRW | -218.837% |
| Peptron, Inc. | -12.65 Billion KRW | 924.107% |
| Amicogen, Inc. | 13.95 Billion KRW | -647.17% |
| Genexine, Inc. | -40.87 Billion KRW | 355.036% |
| HLB Therapeutics Co.,Ltd. | 8.22 Billion KRW | -1166.817% |
| LegoChem Biosciences, Inc. | -71.38 Billion KRW | 246.045% |
| ALTEOGEN Inc. | 440.04 Million KRW | -23591.792% |
| SillaJen, Inc. | -17.35 Billion KRW | 700.801% |
| JETEMA, Co., Ltd. | 11 Billion KRW | -847.094% |
| OliX Pharmaceuticals,Inc | -11.13 Billion KRW | 1036.266% |
| Genomictree Inc. | -6.33 Billion KRW | 1746.502% |
| MedPacto, Inc. | -32.6 Billion KRW | 419.713% |
| D&D Pharmatech | -9.05 Billion KRW | 1250.971% |
| EASY BIO,Inc. | 24.32 Billion KRW | -328.618% |
| GI Innovation, Inc. | -51.33 Billion KRW | 303.103% |